|
|
Keeping the Flu At BayFor Life
Current flu vaccines work by triggering an immune response to two large viral-coat proteins. You are protected against incoming infection, but the problem is that these proteins mutate very frequently in the virus, so the shot you get today is not good for next year, says Dr. Laszlo Otvos, an associate professor in Wistars immunology program who contributed his expertise as a peptide chemist to the project. (Dr. Walter Gerhard, professor of immunology, was senior author of the report in the June issue of the journal Vaccine.)
Another advantage of the engineered vaccine is that it contains no viral particles. (In contrast, a recently approved nasal spray called FluMistdesigned to provide annual protection against the fluis a virus product and cannot be given to patients over 49 because of the rare chance of infection.)
Though FDA approval could be sought for the Wistar vaccine in as little
as two years, a number of tests and questionsremain, Otvos says.
For the next step we really need to see what happens with the virus
when there is evolutionary pressure to mutate the protein. The good
thing here is that this is a short protein, so we can almost anticipate
and can make a construct that could cover all possible permutations.
©
2003 The Pennsylvania Gazette |
GAZETTEER:
News & Sports
|